http://orcid.org/0000-0002-1465-3761
References
- Connor, T.H., and M.A. McDiarmid: Preventing occupational exposures to antineoplastic drugs in health care settings. CA: Cancer J. Clinicians 56(6):354–365 (2006).
- Hon, C.Y., K. Teschke, P.A. Demers, and S. Venners: Antineoplastic drug contamination on the hands of employees working throughout the hospital medication system. Ann Occup Hyg. 58(6):761–770 (2014).
- Janes, A., C. Tanguay, N.J. Caron, and J.F. Bussieres: Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: A study of 51 Canadian Centres. Can. J. Hosp. Pharm. 68(4):279–289 (2015).
- McDiarmid, M.A., M.S. Oliver, T.S. Roth, B. Rogers, and C. Escalante: Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. J. Occup. Environ. Med. 52(10):1028–1034 (2010).
- Favier, B., L. Gilles, C. Ardiet, and J.F. Latour: External contamination of vials containing cytotoxic agents supplied by pharmaceutical manufacturers. J. Oncolo. Pharm. Pract. 9(1):15–20 (2003).
- Fransman, W., R. Vermeulen, and H. Kromhout: Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities. Int. Arch. Occup. Environ. Health 78(5):403–412 (2005).
- Gabay, M.: USP <800>: Handling Hazardous Drugs. Hosp. Pharm. 49(9):811–812 (2014).
- Convention, T.U.S.P.: <800> Hazardous drugs-handling in healthcare settings. In Revision Bulletin, December 1, 2019: United States Pharmacopeial, 2019.
- Connor, T.H., D.G. DeBord, J.R. Pretty, et al.: Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. J. Occup. Environ. Med. 52(10):1019–1027 (2010).
- Yoshida, J., S. Koda, S. Nishida, H. Nakano, G. Tei, and S. Kumagai: Association between occupational exposure and control measures for antineoplastic drugs in a pharmacy of a hospital. Ann. Work Expos. Health 57(2):251–260 (2012).
- Poupeau, C., C. Tanguay, N.J. Caron, and J.-F. Bussières: Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. J. Oncol. Pharm. Pract. 24(1):9–17 (2018).
- Chauchat, L., C. Tanguay, N.J. Caron, S. Gagne, F. Labreche, and J.F. Bussieres: Surface contamination with ten antineoplastic drugs in 83 Canadian centers. J. Oncol. Pharm. Pract. 25(5):1089–1098 (2019).
- Hon, C.-Y., K. Teschke, H. Shen, P.A. Demers, and S. Venners: Antineoplastic drug contamination in the urine of Canadian healthcare workers. Int. Arch. Occup. Environ. Health 88(7):933–941 (2015).
- Boiano, J.M., A.L. Steege, and M.H. Sweeney: Adherence to safe handling guidelines by health care workers who administer antineoplastic drugs. J. Occup. Environ. Hyg. 11(11):728–740 (2014).
- Boiano, J.M., A.L. Steege, and M.H. Sweeney: Adherence to precautionary guidelines for compounding antineoplastic drugs: A survey of nurses and pharmacy practitioners. J. Occup. Environ. Hyg. 12(9):588–602 (2015).